Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
KNOW LABS, INC. (KNWN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 8-K Quarterly results, Conference call transcript
Docs: "Know Labs, Inc. Reports Third Quarter FY2023 Results SEATTLE – August 14, 2023 – Know Labs, Inc. , an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights :",
"Transcript of Earnings Conference Call",
"Presentation"
08/14/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits ...
Docs: "Restatement of the Articles of Incorporation",
"KNOW LABS, INC. SECOND AMENDED AND RESTATED BYLAWS",
"Amended and Restated Series C Certificate of Designation",
"Third Amended and Restated Series C Certificate of Designation",
"Series D Certificate of Correction of Know Labs, Inc.",
"Amended and Restated Series D Certificate of Designation",
"Certificate of Withdrawal of Series F Preferred Stock"
07/26/2023 8-K Quarterly results
06/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "SEATTLE – June 7, 2023 – Know Labs , an emerging developer of non-invasive medical diagnostic technology, revealed the next stage in the development of its proprietary Bio-RFID™ technology – the Generation 1 Device. Gen 1 incorporates Know Labs’ Bio-RFID sensor – which has been proven as technically feasible and stable in delivering repeatable results in measuring blood glucose when used in a lab environment – in a portable device. Currently, there are no medical-grade, commercially available, non-invasive means of measuring blood glucose. The completion of Gen 1 brings Know Labs closer to achieving its ultimate goal of delivering the world’s first FDA-cleared non-invasive blood glucose monitor for the billions of people living with diabetes and pre-diabetes worldwide. The Gen 1 prot..."
05/05/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Know Labs Study Validates Technical Feasibility of its Novel Sensor for Non-Invasive Glucose Monitoring"
04/21/2023 8-K Quarterly results
03/22/2023 8-K Quarterly results
02/02/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "STRATEGIC PARTNERS NEWS RELEASE"
01/27/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Know Labs Announces Executive Leadership Changes and Confirms 2023 Outlook SEATTLE – Jan. 27, 2023 – Know Labs, Inc. , an emerging developer of non-invasive medical diagnostic technology, today announced changes to its executive leadership team. The new structure will help the Company accelerate the development and delivery of its non-invasive medical diagnostics technology, Bio-RFID TM , and better position Know Labs for long-term growth and shareholder value creation. As announced, Ron Erickson, Founder and Chairman at Know Labs, was unanimously named Chief Executive Officer by the Company’s Board of Directors. Erickson has been with the Company and its predecessors for nearly 20 years. He brings 30 years of board, business development, financial and executive leadership experience acros..."
01/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/25/2023 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment 9 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP. Filed herewith",
"Amendment 9 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP. Filed herewith"
01/23/2023 8-K Quarterly results
01/04/2023 8-K Quarterly results
12/09/2022 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment 8 to Senior Secured Convertible Redeemable Note by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith",
"Amendment 8 to Senior Secured Convertible Redeemable Note by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith",
"Amendment 8 to Senior Secured Convertible Redeemable Note by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith",
"Amendment 7 to Senior Secured Convertible Redeemable Note by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith",
"Extension of Warrant Agreement by and between Know Labs, Inc. and Clayton A. Struve. Filed herewith"
12/09/2022 8-K Unregistered Sales of Equity Securities, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment 8 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP. Filed herewith",
"Amendment 8 to Convertible Redeemable Promissory Note dated January 31, 2018, by and between Know Labs, Inc. and J3E2A2Z LP. Filed herewith"
11/16/2022 8-K Investor presentation
Docs: "Know Labs Presentation, 2nd Annual Bernstein CGM Disruptors Conference"
09/21/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, between Know Labs, Inc. and Boustead Securities, LLC",
"Common Stock Purchase Warrant issued by Know Labs, Inc. to Boustead Securities, LLC on September 20, 2022",
"Know Labs, Inc. Announces Closing of $8.28 Million Public Offering of Common Stock SEATTLE – Sept. 20, 2022 – Know Labs, Inc. , an emerging developer of non-invasive medical diagnostic technology, today announced the closing of its underwritten public offering of 4,140,000 shares of its Common Stock at a public offering price of $2.00 per share, which includes the exercise by the underwriter of its over-allotment option to purchase up to 540,000 shares. The gross proceeds from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Know Labs, was $8.28 million. The Common Stock began trading on the NYSE American under the symbol “KNW” on September 16, 2022. Boustead Securities, LLC acted as the sole underwriter, on a firm commitment bas..."
09/19/2022 8-K Other Events  Interactive Data
09/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Know Labs, Inc. Announces NYSE American Listing Approval SEATTLE – Sept. 13, 2022 – Know Labs, Inc. , an emerging leader of non-invasive medical diagnostic technology, today announced that, subject to official authorization and meeting all requirements at the time of listing, the Company has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering of the Company’s common stock. Upon the start of trading on the NYSE American, the ticker symbol for Know Labs’ common stock will change from “KNWN” to “KNW” and the Company’s common stock will cease trading on the over-the-counter market. The stock is expected to commence trading on NYSE American at the opening of trading on September 16, 2022. “The Know Labs team has been working hard to build wh..."
09/02/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Know Labs Provides Update on IRB-Approved Internal Trial of Non-Invasive Glucose Monitoring Technology SEATTLE – Sept. 2, 2022 – Know Labs, Inc. , an emerging developer of non-invasive medical diagnostic technology, today released a video update on the IRB-approved internal trial the Company has been conducting at its laboratory in Seattle. The video can be found here - https://youtu.be/LnYng_Ppq8g. The two-minute video breaks down the trial process, while Know Labs Chief Product Officer Steve Kent explains the protocol for the internal clinical trial and reviews its primary goal, to further refine the algorithm that controls and enables Bio-RFID to identify and measure glucose in the body accurately. The company announced the clinical trial in a news release earlier this year. “Our clinic..."
08/03/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Know Labs Files S-1 for New Share Offering, Seeks Uplist to NYSE American Exchange SEATTLE – August 3, 2022 – Know Labs, Inc. an emerging developer of non-invasive medical diagnostic technology, today announced it has filed a Form S-1 registration statement for a proposed new offering of 3 million shares of its common stock with an anticipated offering price of $2.00 per share. Concurrent with, and as a condition to, the offering, Know Labs will apply to uplist its shares to the NYSE American Exchange. If the uplist is approved, Know Labs shares will cease trading on the OTCQB and will commence trading on the NYSE American, under the proposed new ticker symbol “KNW.” The company intends to use proceeds from the proposed offering for research and development, sales and marketing, general an..."
07/29/2022 8-K Investor presentation
Docs: "Four Page S-1 Product Presentation Insert - Filed herewith"
05/31/2022 8-K Quarterly results
04/05/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "New Foundational Patents Secure Multiple Growth Opportunities for Know Labs and Its Bio-RFID™ Non-Invasive Diagnostic Technology SEATTLE – April 5, 2022 -- Know Labs, Inc. , an emerging leader in non-invasive medical diagnostics, today announced it has been granted two new foundational patents that add significant value to its IP portfolio and proprietary Bio-RFID™ technology. The two patents protect the ability to create and utilize any database built with data captured through non-invasive sensors. This widens the technological gap between Know Labs and others pursuing non-invasive diagnostics, while opening up a much broader range of protection for non-invasive analyte data collection and management, beyond human health. U.S. Patents 11,284,819 and 11,284,820 were issued by ..."
03/08/2022 8-K Quarterly results
02/15/2022 8-K Other Events  Interactive Data
02/03/2022 8-K Quarterly results
01/26/2022 8-K Other Events  Interactive Data
01/05/2022 8-K Other Events  Interactive Data
12/07/2021 8-K Quarterly results
10/21/2021 8-K Other Events  Interactive Data
10/15/2021 8-K Investor presentation
Docs: "Know Labs Annual Shareholder meeting presentation"
10/13/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "New Test Data Confirm Particle™ Bulb from Know Labs Successfully Inactivates SARS-CoV-2 Variants"
10/06/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "New Tests Show Know Labs Bio-RFID™ Technology Delivers Blood Glucose Readings Comparable to FDA-Cleared Devices SEATTLE – October 6, 2021 – Know Labs, Inc. , an emerging leader in non-invasive medical diagnostics, today published a new report on its non-invasive platform technology, Bio-RFID TM , comparing its clinical accuracy to FDA-cleared glucose monitoring devices that are currently available in the market. For these latest tests, human subjects placed their arms on a Bio-RFID sensor and their blood glucose levels were measured every five minutes over a period of two hours. Concurrent readings were taken with an Accu-Chek fingerstick device and with two continuous glucose monitoring devices, Abbott FreeStyle Libre and Dexcom G6, which allowed the calculation of Bio-RFID’s MARD ...."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy